Compare DexCom, Inc. (DXCM) vs Infosys Limited (INFY) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

INFY trades at $11.46, up 3.71% today, with a bearish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 beating expectations. Fundamentals show robust profitability with a net income margin of 16.44% and ROE of 31.57%, while valuation ratios like P/E of 13.8 and EV/EBITDA of 8.5 suggest reasonable pricing. Recent news highlights Infosys' expanding AI collaborations across healthcare, banking, and media sectors.

The outlook is mixed; analyst consensus is a 'Hold' with a $12.14 price target, implying modest upside. Strengths include solid cash flow and AI-driven growth initiatives, but risks involve competitive pressures in IT services and potential volatility from global tech spending trends. The stock presents a value opportunity with steady dividends, though investor sentiment remains cautious amid sector headwinds.